As previously communicated, on 30 January 2024, Nanologica's board of directors resolved on a fully guaranteed rights issue of approximately MSEK 54.2 with preferential rights for existing shareholders, in order to finance intensified investments in preparative chromatography. On 15 March, Nanologica announced that the rights issue had been fully subscribed and that Nanologica through the rights issue, after transaction costs, had received approximately MSEK 40 in cash and cash equivalents in addition to loans corresponding to approximately MSEK 6.2 being offset against shares in the issue.
 
The rights issue has resulted in an increase in the number of shares in Nanologica of 8,032,476 shares during the month of March, from 36,146,142 to 44,178,618 shares. The Extraordinary General Meeting on 22 February 2024 resolved to reduce the share capital by an amount in SEK corresponding to the amount by which the share capital increases through the rights issue. The effect of this decision is that the company's share capital will not increase in connection with the registration of the rights issue but will continue to amount to approximately SEK 14,820,923.
 
As of 28 March 2024, the last trading day of the month, the total number of shares and votes in Nanologica AB amounted to 44,178,618.